The two most well-characterized immune checkpoints targeted by ICIs are the CTLA-4,365,366 and the PD-1/PD-L1 pathways.367 These pathways play distinct but complementary roles in regulating immune responses, and their inhibition has led to significant clinical successes in treating various cancers. This evidence concerns the gene CD274 and cancer.